NEW YORK (360Dx) – Grifols today announced the US Food and Drug Administration has approved the firm's Erytra Eflexis, a fully automated benchtop analyzer for pretransfusion compatibility testing.
The system leverages Grifols' DG Gel technology and can be used as a standalone platform or in combination with Grifols' other blood typing portfolio solutions, the firm said. It added the system facilitates multiple lab configurations and features real random access with a capacity of up to 200 cares, 72 samples, and 46 liquid reagents.
Grifols Commercial Diagnostic Division President Carsten Schroeder noted in a statement that Erytra Eflexis was its seventh FDA diagnostic approval in 2018 and the third approval for its blood typing portfolio. The instrument was CE marked in June 2017.